OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 111 - 120 of 716 studies

Cancer and neoplasms

DRAGON 2 – An international multicenter randomized controlled trial to compare combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE alone. (DRAGON 2)

Resection of liver metastases from colorectal cancer (CRLM) improves survival compared to chemotherapy alone and may lead to cure. In some cases the liver metastasis are considered unresectable. A common reason for this is the lack of enough "tumour free" liver for the patient to survive the operation (Future liver remnant -FLR-). In the event of insufficient FLR, there is a great proportion of patients that will develop liver disfunction that can lead to death (post-hepatectomy liver failure is the ...

GO TO STUDY Go

Oral and Gastrointestinal

A Phase 2a, randomised, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of subcutaneous amlitelimab in adult patients with nonresponsive celiac disease as an adjunct to a gluten-free diet

There are Four treatment groups using a 1:1:1:1 ratio, who will receive a study treatment for 24 weeks. For intervention group amlitelimab + GF, they will have amlitelimab 500mg loading dose followed by a 250mg dose once every four weeks + gluten free products for the full 24 weeks. Intervention group placebo + Gluten free, will have matching placebo and gluten free products for the full 24 weeks. The amlitelimab + SIGE (simulated inadvertent gluten exposure) group, will have amlitelimab ...

GO TO STUDY Go

Oral and Gastrointestinal

A Phase 2a Multicenter, Randomized, Open Label, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn's Disease

This is a Phase 2a PoC, treat-through, multicenter, randomized, open label, platform study in CD subjects. This platform study is designed as a series of "intervention sets" that will run in parallel but may not be initiated at the same time. Each intervention set will include 1 or more treatment arms depending on the objective of the intervention set. In addition, 1 treatment arm will be incorporated as a common comparator arm across other intervention sets. Additional "intervention sets" and/or ...

GO TO STUDY Go

Cancer and neoplasms

Brief Intervention with Cyclophosphamide in Patients with Colorectal Cancer Who Completed Treatment (BICCC)

Bowel cancer is one of the leading causes of cancer-related deaths worldwide. In the early stages of the disease, many patients can be cured with surgery. However, in the later stages, bowel cancer can return or progress even after surgery and chemotherapy. One potential way of preventing relapse is by making the patient’s immune system better at detecting and destroying any cancer cells that might remain after treatment. T cells are a type of white blood cell that play a ...

GO TO STUDY Go

Cancer and neoplasms

Direct to Patient Testing at Cancer Diagnosis for Precision Prevention-2 (DETECT-2)

All patients who are diagnosed with womb, bowel, or ovary cancer are recommended to have genetic-testing to see if their cancer was related to an inherited gene alteration. Identifying carriers of alterations allows novel personalised cancer treatments, prevention of second cancers, and testing of family members for cancer screening and prevention. Genetic testing requires pre-test counselling to ensure patients are informed about the impact of having a genetic test and managing the result. This ‘genetic-counselling’ has traditionally been provided by genetics ...

GO TO STUDY Go

Inflammatory and immune system Reproductive health and childbirth

The Monoclonal Antibody Medications in inflammatory Arthritis: stopping or continuing in pregnancy (MAMA) trial

The Monoclonal Antibody Medications in inflammatory Arthritis (MAMA) trial is designed to address the significant uncertainty and resulting variation in practice surrounding the effects of continuing or stopping biologics during pregnancy. There are no randomised trials which compare stopping or continuing biologics in head-to-head studies in an Autoimmune Inflammatory Arthritis (AIA) population. This study aims to fill the gap in evidence and enable evaluation of arthritis disease activity,pregnancy,and infant outcomes in women randomly allocated to continuing their biologic medication throughout ...

GO TO STUDY Go

Cancer and neoplasms

CT7439_001 - A Modular, Multi-Part, Multi-Arm, Phase 1/2 Study to Evaluate the Safety and Tolerability of CT7439 Alone and in Combination with Anticancer Treatments in Participants with Solid Malignancies

This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies. Module 1 will initially focus on monotherapy in participants with locally advanced or metastatic solid malignancies and include dose escalation cohorts (Part A) and dose optimization cohorts (Part B) (Appendix A). In Parts A and B of Module 1, a SRC, consisting of study investigators and sponsor medical ...

GO TO STUDY Go

Cancer and neoplasms

TOURIST: Thoracic Umbrella Radiotherapy study in stage IV NSCLC. PRINCE: Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in stage IV non-small cell lung cancer. QUARTZ LUNG: Quality of life after radiotherapy treatment for patients with stage IV non-small cell lung cancer (TOURIST PRINCE)

Radiotherapy to the chest is widely used in the treatment of lung cancer. Its use in stage IV non-small cell lung cancer (NSCLC) has evolved worldwide based on local experience, as doctors attempt to ease symptoms, maintain/improve quality of life, and prolong survival, while minimising side effects. Current palliative thoracic radiotherapy practice is still based on dose fractionations that were studied in the 1990s. However, the past 30 years have seen profound changes in the management of advanced lung cancer, ...

GO TO STUDY Go

Cancer and neoplasms

PROPEL: Evaluation of PeRsOnalised PrEhabilitation in people with acute myeloid Leukaemia (PROPEL)

Acute myeloid leukaemia (AML), is an ‘aggressive’ blood cancer with only around 20% of affected adults surviving at 5 years. AML often presents as a medical emergency and treatment is intensive. After the initial course of urgent anticancer therapy, people with AML receive repeated intensive courses of chemotherapy aimed at cure, that may include ‘haemopoietic’ (blood) stem cell transplantation. They need to remain in hospital during courses of treatment, often in isolation, due to risk of infection, with short periods ...

GO TO STUDY Go

Blood Generic health relevance

Scaled collection of socioEconomic and Quality of Life data from patients undergoing allogeneic haematopoietic cell transplantation (SEQoL)

1. Study design 1.1. Patient and Public Involvement (PPI) PPI remains central to this project,with the Anthony Nolan Patient Services team co-developing the proposal alongside a Patient Advisory Group (PAG). The PAG,consisting of 6 allogeneic HCT patient representatives,has been expanded to include members from underserved and minority groups to ensure diverse perspectives. PAG members actively participated in online meetings and in-person workshops,contributing to research design and sampling timepoints,providing feedback on questionnaire content and measures,and assisting in the development of patient-facing study ...

GO TO STUDY Go